Stimulation of b-adrenergic receptors (b-AR) increases cAMP production and contributes to the pathogenesis of cardiac hypertrophy and failure through poorly understood mechanisms. We previously demonstrated that Exchange protein directly activated by cAMP 1 (Epac1)-induced hypertrophy in primary cardiomyocytes. Among the mechanisms triggered by cardiac stress, autophagy has been highlighted as a protective or harmful response. Here, we investigate whether Epac1 promotes cardiac autophagy and how altered autophagy has an impact on Epac1-induced cardiomyocyte hypertrophy.
Introduction
b-Adrenergic receptor (b-AR) serves as the most powerful regulatory mechanism to enhance myocardial performance in response to emotional stress or exercise. Acute stimulation of b-AR via catecholamines leads to activation of adenylyl cyclases and increases cAMP production to enhance myocardial function. 1 Meanwhile, chronic activation of b-AR leads to cardiac hypertrophy and ventricular dysfunction and ultimately to the development of chamber dilatation and heart failure (HF). 2 Cardiac effects of cAMP were classically attributed to phosphorylation events catalyzed by cAMP-dependent protein kinase (PKA). More recently, a family of proteins directly activated by cAMP, named Epac (Exchange proteins directly activated by cAMP, and its 2 isoforms, Epac1 and Epac2) was discovered as an important new mechanism for cAMP-mediated signalling. 3 Epac are guanine nucleotide exchange factors (GEFs) for Ras-like small GTPase family members, Rap1 and Rap2 and function in a PKA-independent manner. 3 Upon binding to cAMP, Epac promotes the exchange of guanosine diphosphate for † Co-first authors. ‡ These authors contributed equally to this work.
guanosine triphosphate (GTP), thereby inducing the activation of the small G protein Rap. Several studies point to Epac1 as a new important signalling molecule in the heart. Indeed, Epac1 is up-regulated both in experimental animal models of cardiac hypertrophy and in the late stage of human failing hearts. 4, 5 Epac1 is also an important regulator of cardiac contractility through PKA-independent phospholamban phosphorylation and sarcomeric protein phosphorylation. 6, 7 In addition,
we recently demonstrated that Epac1 induced cell growth in cultured adult ventricular myocytes by rapidly inducing Ca 2+ mobilization and pro-hypertrophic transcription factors activation. 8, 9 Among the mechanisms triggered by cardiac stress, recent studies have highlighted autophagy, an evolutionary conserved self-degradation pathway that plays a crucial role in the removal of damaged intracellular constituents for maintaining cellular homeostasis. 10 In the setting of pathological cardiac remodelling, there is increasing evidence that cardiac autophagy is up-regulated and may antagonize ventricular hypertrophy by increasing protein degradation which decreases ventricular mass. 10 However, excessive autophagy induction can also trigger cardiomyocyte death and then may contribute to the disease progression, underlining its Janus-faced role that could be either protective or harmful depending on the nature of the stimulus, and on the level and duration of autophagy. Therefore, in the present study we sought to address: (i) whether cardiomyocyte autophagy is induced in response to the activation of Epac1 and what are the signalling mechanisms underlying Epac1-triggered autophagy if any; (ii) whether the genetic deletion of Epac1 prevents ventricular hypertrophy and autophagic activity during prolonged b-AR activation; and (iii) how altered autophagy has an impact upon Epac1-induced cardiomyocyte hypertrophy.
Our results reported that b-AR-Epac1 activation promoted autophagic activity in rat primary cardiomyocytes and mice hearts. Interestingly, in response to chronic b-AR stimulation, ventricular hypertrophy as well as autophagy activation was prevented in Epac1 knock-out mice (Epac1 2/2 ). Moreover, we showed that inhibition of autophagy potentiated Epac1-induced cardiomyocyte hypertrophy. Mechanistically, we provided evidence that Epac1-induced autophagy was mediated by a Ca 2+ /calmodulin-dependent kinase kinase b (CaMKKb)/AMP-dependent protein kinase (AMPK) signalling pathway.
Methods

Reagents and products
3-Methyladenine (3-MA), Bafilomycin A1 (Baf1), Rapamycin, BAPTA-AM, STO-609, Chloroquine (CQ), and Isoprenaline (ISO) were purchased from Sigma-Aldrich. The non-hydrolysable Epac agonist Sp-8-(4-chlorophenylthio)-2 ′ -O-methyl-cAMP (Sp-8-pCPT) was from BioLog. The Epac1 inhibitor CE3F4 was synthesized according to the methods published previously. 
Cell culture
All procedures for neonatal rat ventricular myocytes (NRVMs) isolation were performed in accordance with the Guide for the care and use of laboratory animals and the veterinary committee has been informed of the cardiac myocyte isolation protocol used. Neonatal rats of 1 -2 days old were euthanized by decapitation, hearts excised and atria were removed. Primary culture of NRVMs was performed as described previously. 12 
Plasmid constructs and transfection
The plasmid constructs were generously provided by the following: rat ANF promoter fused to the luciferase reporter gene (ANF-Luc) by 
SiRNA experiments
Rat Rap2B (5 ′ -GCCUCAGUGGAUGAGCUAU-3 ′ ) and Atg5 (5 ′ -CAACG UGCUUUACUCUCUA-3 ′ ) siRNA specific and control siRNA were reconstituted at 100 mM (Ambion). One day after NRVMs plating, transfection was performed with DharmaFECT w Duo (Thermo Scientific) in the presence of 0.5 nmol of siRNA per well.
NRVM surface area
Determination of the NRVM surface area was performed as described previously. 12 Briefly, cardiomyocytes were stained with an anti-a-sarcomeric actinin (Sigma-Aldrich) and a secondary antibody coupled to Alexa Fluor w 546 (Molecular probes) and were then analysed by confocal laser microscopy (Zeiss LSM510). Photographic images of NRVMs were digitized and the areas of 100 -200 cells per condition from at least three independent experiments were analysed by computer-assisted planimetry.
Autophagic vacuole staining
Autophagic vacuoles were detected by fluorescence microscopy using the Cyto-ID TM autophagy detection kit (Enzo Life Sciences). Live cells were analysed by fluorescence microscopy at 600× magnification. Fluorescence intensity was quantified using the ImageJ software (RSB).
Autophagic flux assessment
For in vitro autophagic flux assessment, NRVMs were treated with either vehicle or 50 nM bafilomycin A1 (Sigma-Aldrich) for 1 h and cell lysates were prepared for the detection of LC3 protein level. For in vivo autophagic flux assessment, mice were injected intraperitoneally with vehicle or 50 mg/kg chloroquine (Sigma-Aldrich) and the hearts were dissected 6 h after injection for the analysis of LC3 protein level.
Western blot analysis
Proteins were separated by SDS -PAGE and transferred to polyvinylidene difluoride membranes (Millipore) as described previously. 12 The membranes were incubated with the primary antibodies Epac1 (Novus Biological), LC3 (Cell Signaling), Beclin 1 (Cell Signaling), GAPDH (Cell Signaling), p-AMPK (Cell Signaling), total AMPK (Santa Cruz) or p62 (Abcam) and followed by incubation with peroxidase-conjugated secondary antibodies (Cell Signaling). Immunoblots were revealed by using enhanced chemiluminescence West Dura (Thermo Scientific). Signals were quantified by densitometry using the Image Lab software (Bio-Rad).
Immunoprecipitation
After appropriated treatment, NRVMs were lysed with a buffer containing 20 mmol/L Tris, pH 7.5, 150 mmol/L NaCl, 20 mmol/L MgCl 2 , 0.5% NP40, 0.5 mmol/L EDTA, protease, and phosphatase cocktail inhibitors (Roche). Beclin 1 was immunoprecipitated using an antibody against Beclin-1 (Cell Signaling). Purification steps were performed with protein A/G agarose according to the manufacturer's instructions (Santa Cruz). Samples were subjected to immunoblotting using a primary antibody against Bcl-2 (Cell Signaling) and a secondary antibody that recognizes only native IgG (Cell Signaling).
Determination of fibrosis
Hearts were transversely sectioned at 10 mm thickness, fixed with 4% paraformaladehyde, and stained with Masson's Trichrome. Slides were scanned with NanoZoomer (Hamamatsu v1.2) and fibrosis was measured as positively stained area with Masson's Trichrome and expressed as per cent of total area, using ImageJ software (RSB).
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Chronic ISO infusion
Osmotic mini-pumps (Alzet) were implanted subcutaneously in mice anaesthetized with isoflurane (1%). Pumps were filled with ISO or sterile saline and were set to deliver ISO at 30 mg/kg per day for 28 days. Mice were subsequently euthanized with barbiturate overdose (pentobarbital, 150 mg/kg, i.p.) and mini-pumps were weighed in order to verify complete diffusion.
Echocardiograhy
Echocardiography was carried out on lightly anaesthetized (1% isoflurane in air) mice placed on a heating pad. The left ventricle dimensions were obtained during TM mode acquisition from the parasternal short-axis view at the level of the papillary muscles using a Vivid7 echograph and a 14 MHz transducer (i13L, GE Healthcare). Images were transferred and analysed off line with EchoPAC (GE Healthcare). The operator was blind to the genotype of the mice.
Ventricular cardiomyocyte surface area
Hearts were transversely sectioned at 7 mm thickness, rehydrated in H 2 O, fixed with 4% paraformaldehyde, and permeabilized with Triton (Molecular Probes, Image-iT w Fix-Perm kit). Cryoslices were incubated with a mouse monoclonal anti-vinculin antibody (Sigma-Aldrich) for 2 h. Cells were then incubated with a goat anti-mouse secondary antibody coupled to Alexa Fluor w 488 (Molecular Probes). Images of stained cardiomyocytes were acquired on Zeiss Observer Z.1 microscope (Carl Zeiss) at ×160 Autophagy antagonizes Epac1-induced cardiac hypertrophy magnification. The outlines of a least 300 circular to oval-shaped cardiac myocytes were traced in four fields from at least three different mouse samples by using Axio Vision Rel 4.7 software (Carl Zeiss).
Statistical analysis
Results are expressed as mean + SEM. Differences between two groups have been analysed by an unpaired two-tailed Student's t-test. Differences between more than two groups were analysed by one-way analysis of variance (ANOVA) with Bonferroni's post hoc test for multiple comparisons or a two-way ANOVA followed by Bonferroni post-test if necessary. Statistical significance was set to P , 0.05.
Study approval
Mouse experiments in this study were performed with the approval of the Comité d'éthique régional Midi-Pyrénées.
Results
Epac1 activation triggers autophagy in neonatal cardiac myocytes
We investigated whether Epac1 activation can elicit autophagy in cultured NRVMs. Evidences for Epac1-induced autophagy activity were obtained by measuring the appearance of the lipidated form of LC3 (LC3-II), the expression of Beclin 1 and the increased number of autophagosomes. As shown in Figure 1A , LC3-II and Beclin 1 levels compared with control, were increased in NRVMs treated with the Epac-selective and non-hydrolysable cAMP analogue, Sp-8-pCPT. Since autophagy activation can induce the dissociation of the Beclin 1-Bcl-2 complex in cardiomyocytes, 13 we investigated the effect of Sp-8-pCPT treatment on the interaction between Beclin1 and Bcl-2. Immunoprecipitation of Beclin1 followed by probing for Bcl-2 indicated that Epac1 activation enhanced the dissociation between Beclin1 and Bcl-2 (see Supplementary material online, Figure S1 ). Epac1-induced autophagy activation were also confirmed by fluorescence imaging using the Cyto-ID w Green fluorescent dye, which showed a significant increase in autophagic puncta with Sp-8-pCPT treatment ( Figure 1B) . Increased level of LC3-II is not a measure of autophagic flux per se, but can reflect both the induction of autophagy and/or inhibition of autophagic degradation. 14 To investigate the flux through the autophagic pathway, the gold standard method uses the lysosomal protease inhibitor Bafilomycin A1 (Baf1). NRVMs stimulated with Sp-8-pCPT in the presence of Baf1 displayed increased LC3-II levels compared with cells treated with Sp-8-pCPT alone, indicating that Epac1 activation-induced autophagy flux ( Figure 1C ). Of note, we found that a non-selective b-AR agonist, ISO mimicked the effect of Epac1 activation on LC3-II expression ( Figure 2A) . b-AR activation-induced autophagy flux was dependent on 
prevented the increase of LC3-II in the presence of Baf1 in ISOstimulated NRVMs (Figure 2A) . Moreover, the autophagic flux induced by ISO or inhibited by CE3F4 pre-treatment was validated by an increase in autophagic puncta ( Figure 2B ). The increase in LC3-II and Beclin 1 expression as well as autophagic vacuoles induced by treatment with the Epac agonist, Sp-8-pCPT, was prevented by CE3F4, indicating that the CE3F4 compound was specific of Epac1 (see Supplementary material online, Figure S2) . Finally, the enhanced expression of Beclin 1 was also prevented by CE3F4 in ISO-stimulated NRVMs ( Figure 2C) . Altogether, these data demonstrated that b-AR via Epac1 promoted autophagy process in NRVMs.
Signalling mechanisms involved in Epac1-induced autophagy
The small GTPases, Rap1 and Rap2, are direct effectors of Epac proteins. 3 We have previously shown that Epac1 hypertrophic signalling involves Rap2B-dependent stimulation of phospholipase C, leading to IP 3 production and a subsequent increase in intracellular Ca 2+ . 8, 9 Therefore, we evaluated the requirement of Rap2B and Ca 2+ signalling on the activation of autophagy by Sp-8-pCPT in NRVMs. As shown in Figure 3A , down-regulation of Rap2B with specific siRNA (siRap2B) decreased Figure 3C) . Therefore, our results indicate that the signalling mechanisms underlying Epac1-induced autophagy involved a Ca 2+ /CaMKKb/AMPK pathway.
Epac1
2/2 mice are protected against b-AR-induced cardiac hypertrophic remodelling
We next sought to determine whether Epac1 was involved in cardiac hypertrophic remodelling associated with autophagy activity in , 8 h) . Immunoblot analysis of LC3 proteins and AMPK thr172 phosphorylation levels were performed on NRVMs protein extracts. GAPDH expression was used as loading control. The graphs represent quantification of LC3-II and AMPK thr172 phosphorylation levels measured by densitometry analysis. n ¼ 4. Statistical significance was determined by two-way ANOVA followed by Bonferroni post-test. *P , 0.05, **P , 0.01 compared with indicated values.
Autophagy antagonizes Epac1-induced cardiac hypertrophy response to a chronic activation of b-AR. We generated Epac1 2/2 mice by crossbreeding a LoxP-Epac1 mouse line with the Desmin-CRErecombinase line (see Supplementary material online, Figure S3A ). Deletion of the genomic region between the loxP sites was confirmed by PCR. Quantitative PCR (see Supplementary material online, Figure  S3B ) and western blot analysis of cardiac extracts of Epac1 2/2 mice did not detect Epac1 ( Figure 4A ). Moreover, there was no compensatory change in the Epac2 isoform (see Supplementary material online, Figure  S3B ). Epac1 2/2 mice appeared healthy and had similar body weights to those of wild-type littermates (Epac1 +/+ ) (see Supplementary material online, Figure S3C ). The ratio of heart weight (HW) to tibia length (TL) (HW/TL) and left ventricular weight (LVW) to tibia length (LVW/TL) of Epac1 +/+ and Epac1 2/2 mice were similar at baseline ( Figure 4B ).
Chronic infusion of ISO resulted in a significant increase in HW/TL (35.4% vs. saline) and LVW/TL (35.7% vs. saline) ratios compared with control vehicle ( Figure 4B ). Conversely, Epac1 2/2 mice treated with ISO showed only a 21 and 18% increase in HW/TL and LVW/TL ratios, respectively ( Figure 4B) . Interestingly, deletion of Epac1 further decreased left ventricular dilatation which was associated with a better cardiac function as shown by a higher increase in fractional shortening (FS) after ISO infusion ( Figure 4C ). Basal and ISO-induced heart rate were equivalent in Epac1 +/+ and Epac1 2/2 mice (data not shown). The size quantification of cardiomyocytes from heart cryosections revealed that the deletion of Epac1 significantly prevented ISO-induced cardiac myocyte hypertrophy ( Figure 5A) . Moreover, the up-regulation of the hypertrophic gene markers, atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP) was also compromised in Epac1 2/2 mice compared with Epac1 +/+ mice ( Figure 5B) . Accordingly, we found a significant reduction in fibrosis and fibrotic markers of Epac1
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hearts compared with Epac1 +/+ littermates under ISO treatment ( Figure 5C and D). Altogether these data allow us to conclude that Epac1 is involved in cardiac hypertrophic remodelling in response to chronic activation of b-AR.
Deletion of Epac1 prevents the induction of cardiac autophagy
We next examined the autophagy status in ISO-treated Epac1 2/2 mice compared with control Epac1 +/+ mice. The expression of LC3-II and Beclin 1 ( Figure 6A ) failed to increase in ventricular lysates of ISO-treated Epac1 2/2 mice compared with ISO-treated Epac1 +/+ mice. Interestingly, levels of p62, a protein receptor that brings ubiquitinated aggregates and gets degraded during autophagy, were significantly elevated in the hearts of Epac1 +/+ mice under ISO treatment but not in the hearts of Epac1 2/2 mice ( Figure 6B ). The increased autophagic flux was then determined in vivo by LC3 immunoblotting after administration of the lysosomotropic drug chloroquine (CQ) which neutralizes lysosomal pH and impairs autophagosome fusion with lysosomes. 16 As shown in Figure 6C , the increased LC3-II level LVIDs, left ventricular end-systolic diameter; FS, fractional shortening. Statistical significance was determined by two-way ANOVA followed by Bonferroni post-test. *P , 0.05, **P , 0.01, *** P , 0.001 compared with compared with control values or indicated values.
Impaired autophagy potentiates cardiomyocyte hypertrophy induced by Epac1 activation
Although increased autophagic activity in cardiomyocytes has been demonstrated in the setting of cardiovascular stress such as ischaemia/ reperfusion and pathological remodelling, its function is not completely understood. Current studies suggest that autophagy can have both beneficial and damaging roles in the heart depending on the context and the level of autophagy activation. Therefore, to find out the functional role of increased autophagy induced by Epac1 activation, we manipulated autophagic activity by both pharmacological and RNA interference approaches. NRVMs were pre-treated with 3-methyladenine (3-MA), an inhibitor of class III phosphoinositide-3-kinase which is required for initiation of autophagosome formation. As shown in Figure 7A and B, 3-MA pre-treatment further increased the expression of hypertrophy markers induced by either Sp-8-pCPT or Epac1 plasmid transfection as measured by the transcriptional activity of ANF or skeletal muscle (SkM)-a-actin promoter coupled to the luciferase gene (Luc). Similarly, silencing autophagy-related protein 5 (Atg5), an E3 ubiquitin ligase involved in autophagosome elongation, 17 potentiated the expression of ANF hypertrophic marker in NRVMs transfected with Epac1 ( Figure 7C) . On the contrary, the pre-treatment of NRVMs with the autophagy inducer rapamycin reduced Epac1-induced ANF hypertrophy marker expression ( Figure 7D ). Cardiomyocyte hypertrophy is also typically characterized by cell enlargement and enhanced sarcomeric organization. As shown in Figure 7E , Atg5 silencing induced a higher significant increase in cell surface area in NRVMs treated with Sp-8-pCPT compared with control siRNA.
Taken together our results demonstrate that the inhibition of autophagy potentiates cardiomyocyte hypertrophy induced by the activation of Epac1 and support a beneficial role for autophagy as a compensatory mechanism to counteract the cardiac hypertrophic effect of Epac1.
Discussion
The results of the present study revealed a key role of Epac1 in the induction of autophagy during pathological cardiac hypertrophy. We demonstrated, for the first time, that the activation of Epac1 triggered autophagy in cardiac myocytes. The critical role of Epac1 was further supported by our data obtained in Epac1 2/2 mice since Epac1 deletion protected against b-AR induced cardiac remodelling and prevented the induction of autophagy. Accordingly, these in vivo results corroborated our previous in vitro findings showing that Epac1 led to cardiac myocytes hypertrophy through Ca 2+ /Calcineurin/CaMKII activation 5, 12 and, confirmed in vivo that Epac1 is a new important signalling protein in the heart. Interestingly, we shed new light on the role of autophagy induced by Epac1 activation since autophagy inhibition potentiates the cardiac myocyte hypertrophic effect of Epac1. The conserved autophagiclysosomal pathway is necessary for normal cardiac function but recently autophagy has received increasing attention since its deregulation resulting in either excessive or insufficient autophagy may contribute to myocardial dysfunction and HF. 18, 19 Although controversy has surrounded the role for autophagy in the hypertrophic heart, 20 we provided in vitro and in vivo convincing evidence that (i) Epac1 promoted autophagy activity during cardiac remodelling and (ii) inhibition of autophagy potentiated cardiac myocyte hypertrophy activated by Epac1. Indeed, we As mentioned above, current literature reported contradictory results about the functional beneficial or detrimental role of enhanced autophagy in cardiac diseases. In our experimental conditions, the inhibition of autophagy with 3-MA or siAtg5 potentiated Epac1-induced cardiomyocyte hypertrophy whereas stimulation of autophagy with rapamycin prevented the hypertrophic effect of Epac1. In view of these findings, we put forward that in the setting of the cardiac remodelling induced by Epac1 activation; autophagy is likely an adaptive mechanism that antagonizes the effect of Epac1. This makes sense since autophagy functions to scavenge dysfunctional organelles and modified proteins to avoid cellular toxicity. Our hypothesis is also strengthened by the results obtained in the mice model of ventricular remodelling. Indeed, chronic infusion of ISO for 28 days induced Epac +/+ cardiomyocyte hypertrophy without alteration of the cardiac function (an increase in the FS was measured in ISO-treated wild type mice). Thus, the observed ventricular remodelling could be considered as a compensated hypertrophic status in which the activation of autophagy plays a cardioprotective role to eliminate the accumulation of misfolded and ubiquitinated proteins. We extended our work to decipher the signalling pathway that accounted for Epac1-activated autophagy. We showed that Epac1 induced autophagy through its downstream effectors Rap2B GAPDH expression was used as loading control. The graph represents quantification of p62 levels measured by densitometry analysis. (C) Autophagic flux assessment were performed on LV homogenates of Epac1 +/+ mice or Epac1 2/2 mice treated or not with ISO for 28 days based on changes in LC3-II levels elicited by chloroquine (CQ, 50 mg/kg) treatment, (n ¼ 6 to 7 per experimental group). GAPDH expression was used as loading control. The graphs represent quantification of LC3-II levels measured by densitometry analysis. Statistical significance was determined by two-way ANOVA followed by Bonferroni post-test. *P , 0.05, **P , 0.01, ***P , 0.001 compared with indicated values. ns, non-significant.
with the Ca 2+ chelator BAPTA-AM and siRap2B. This is also in agreement with previous studies showing that chronic b 2 -AR stimulation by formoterol triggered skeletal muscle hypertrophy and autophagylysosomal pathway activation. 24 The hypertrophic effect of formoterol is mediated through the activation of the Akt-mTOR pathway that could possibly involve the activation of Epac by cAMP. However, it is currently unknown whether Epac1 may mediate crosstalk between b-AR and Akt-mTOR pathway in the setting of cardiac hypertrophy. Interestingly, our findings rise the intriguingly question about the regulation of autophagy by cAMP. Previously, in the setting of the identification of new autophagy-inducing drugs, Williams et al. 25 reported in COS-7 cells the deleterious effects of the Epac-specific cAMP analogue (8-CPT-2-Me-cAMP) on HDQ74 (a mutant huntingtin) aggregation which were abrogated by a dominant-negative mutant of Rap2B (Rap2B S17N ). From their data showing that LC3-II expression was induced by a transfected Rap2B S17N , they concluded on the importance of Epac as a negative regulator of autophagy. In addition, Mestre et al.
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proposed that increased cAMP levels upon bacterial infections inhibited a-hemolysin-induced autophagic response through Epac/Rap2B/PLC1 and via IP3/calpain activation that cleaves Atg5. Their findings contrast with our data but these discrepancies are difficult to interpret conclusively since the cellular model and the pathological context studied are different. Because our data presented here are mainly based on endogenous Epac1 signalling activation, we believe that our findings reflect physiological circumstances. Furthermore, since Epac signalling is spatially and temporally regulated by diverse anchoring mechanisms which control specific functions of this cAMP-sensitive GEF by recruitment to distinct subcellular locations, 3 we cannot exclude the possibility that cell-type-specific signals contribute to different autophagy regulation. In addition, as cAMP signalling and outcomes are highly complex processes; this versatility could be interpreted as an important tool allowing the fine tuning of the cellular responses to particular environment. 15 However, to our knowledge, our study is the first to report a role of CaMKKb and AMPK in the regulation of cardiac autophagy. Interestingly, the Epac1/Ca 2+ /CaMKKb/AMPK signalling pathway described in our study is further support by the work of Park et al.
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Indeed, the authors demonstrated that resveratrol through competitive inhibition of cAMP-degrading phosphodiesterases led to elevated cAMP levels and subsequent activation of Epac1 resulting in Ca 2+ /CaMKKb/ AMPK pathway activation via the phospholipase C and the ryanodine receptor. Hence, our current data have highlighted a novel Ca 2+ signalling pathway downstream Epac1 activation involved in autophagy induction.
In conclusion, our data led us to propose a scenario in which b-AR stimulates Epac1 via cAMP, thereby activating Rap2B and PLC to induce the release of intracellular Ca 2+ . In response to Ca 2+ increase, CaMKKb is stimulated and induces the phosphorylation of AMPK which ultimately leads to mTORC1 inhibition and activation of adaptive autophagy to antagonize Epac1-induced pathological cardiac remodelling.
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